Key result
Agomelatine (20 mg/kg) approximately halved cisplatin-related increases in serum creatinine, BUN, AST, and ALT levels in animals, though the 40 mg/kg dose failed to show the same liver benefits.
Why the study?
Nephrotoxicity and hepatotoxicity are frequent adverse effects during cisplatin chemotherapy, prompting investigation into whether agomelatine protects against cisplatin-induced kidney and liver toxicity.
Does agomelatine prevent cisplatin-induced nephrotoxicity and hepatotoxicity in an animal model?
Does agomelatine prevent cisplatin-induced nephrotoxicity and hepatotoxicity in an animal model?
Agomelatine at 20 mg/kg protects against cisplatin-induced nephrotoxicity and hepatotoxicity in an animal model, though higher doses may pose a risk of hepatotoxicity.
Agomelatine attenuated cisplatin renal and hepatic injury in rats; leaves open clinical translation and optimal dosing.
Nephrotoxicity and hepatotoxicity are frequently seen adverse effects during cisplatin chemotherapy. In this study, we investigated the effects of agomelatine on cisplatin-induced toxicity in the kidney and liver. Animals were administered with a single dose of cisplatin (7 mg/kg, i.p.) and treated with agomelatine (20 and 40 mg/kg, p.o) for seven days. Renal and hepatic functions were evaluated by measuring concentrations of creatinine, BUN, AST and ALT in the serum. Oxidative stress and protein peroxidation were assessed by measuring SOD, CAT, GSH and AOPP levels in both tissues. Serum PON-1 levels were also evaluated. Histopathological analysis was performed to determined structural changes in the kidney and liver. Agomelatine (20 mg/kg) treatment approximately halved cisplatin-related increase in serum creatinine, BUN, AST and ALT levels. Agomelatine (20 mg/kg) significantly prevented the cisplatin-induced excessive decrease in SOD, CAT, GSH in both tissues and serum PON-1 levels. Agomelatine (20 and 40 mg/kg) protected the structural integrity of the kidney against cisplatin-insult. Although agomelatine (40 mg/kg) protected the kidney and showed parallel results with 20 mg/kg biochemically, it failed to show the same liver tissue effects in both analyses. Although agomelatine protected against cisplatin-induced toxicity in the kidney and liver, care should be taken with higher doses for possible hepatotoxicity.
No takes yet. Share an insight, caveat, or question.
Çankara et al. (2022) studied Cisplatin-induced toxicity. Agomelatine vs. Cisplatin alone was evaluated on Renal and hepatic functions (creatinine, BUN, AST, ALT) and oxidative stress markers. Agomelatine (20 mg/kg) approximately halved cisplatin-related increases in serum creatinine, BUN, AST, and ALT levels in animals, though the 40 mg/kg dose failed to show the same liver benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: